

Disclosures

Personal Commercial (6)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
GossamerBio	Consultant Fees/Honoraria	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Janssen Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Merck	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Tenax Therapeutics	Stock	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
united therapeutics	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (2)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
CMREF	Research/Research Grants	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
NIH	Research/Research Grants	Significant (>= \$5,000)	Other

Clinical Trial Enroller (2)

Trial Name	Trial Sponsor	Trial Funding Source
Metformin in PAH	National Institutes of Health	National Institutes of Health
PHANTOM	National Institutes of Health	National Institutes of Health

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
Self				
2014	diet drug litigation	Defendant	diet drug litigation	Modest (< \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 6/4/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 6/4/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 6/4/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 6/4/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.